Evofem Biosciences Inc. has announced an amendment to its Development and Supply Agreement with Pharma 1 Drug Store L.L.C., a limited liability company based in the United Arab Emirates. The amendment, signed on May 3, 2025, introduces a new 3-applicator package size of the Licensed Product, in addition to the existing 12-applicator package. This strategic move aims to enhance product offerings and meet diverse consumer needs. The full details of the amendment are available in the company's Current Report on Form 8-K.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.